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Pancreatic ductal adenocarcinoma (PDA) is characterized by abun-
dant desmoplasia and poor tissue perfusion. These features are
proposed to limit the access of therapies to neoplastic cells and
blunt treatment efﬁcacy. Indeed, several agents that target the
PDA tumor microenvironment promote concomitant chemother-
apy delivery and increased antineoplastic response in murine
models of PDA. Prior studies could not determine whether chemo-
therapy delivery or microenvironment modulation per se were the
dominant features in treatment response, and such information
could guide the optimal translation of these preclinical ﬁndings to
patients. To distinguish between these possibilities, we used a
chemical inhibitor of cytidine deaminase to stabilize and thereby
artiﬁcially elevate gemcitabine levels in murine PDA tumors
without disrupting the tumor microenvironment. Additionally, we
used the FG-3019 monoclonal antibody (mAb) that is directed
against the pleiotropic matricellular signaling protein connective
tissue growth factor (CTGF/CCN2). Inhibition of cytidine deaminase
raised the levels of activated gemcitabine within PDA tumors with-
out stimulating neoplastic cell killing or decreasing the growth of
tumors, whereas FG-3019 increased PDA cell killing and led to a dra-
matic tumor response without altering gemcitabine delivery. The
response to FG-3019 correlated with the decreased expression of
a previously described promoter of PDA chemotherapy resistance,
the X-linked inhibitor of apoptosis protein. Therefore, alterations in
survival cues following targeting of tumor microenvironmental fac-
tors may play an important role in treatment responses in animal
models, and by extension in PDA patients.
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Pancreatic ductal adenocarcinoma (PDA) remains a uniformlylethal disease with a catastrophic 5-y survival rate of less than
5% (1). Despite intensive preclinical and clinical research efforts
to tackle this disastrous disease, the oncologic management of
PDA patients has hardly changed over the last several decades.
The poor responsiveness to standard single and combination
chemotherapies is reﬂected in a median survival of 6–11 mo in
advanced disease, and emphasizes the desperate need for novel
therapies (2, 3). A striking histological feature of PDA is the
extremely dense and highly abundant tumor stroma consisting of
activated cancer-associated ﬁbroblasts (CAFs), inﬁltrating im-
mune cells, and perturbed vascular cells that form a reactive,
inﬂammatory, immunosuppressive, and highly dynamic tumor
microenvironment around neoplastic ductal cells. More than in
any other solid malignancy, this microenvironmental network of
soluble cytokines, growth factors, proteases, and additional ex-
tracellular matrix (ECM) components has increasingly been
appreciated to support cancer cell proliferation, differentiation,
invasion, early metastasis, and therapeutic resistance in PDA
(4–7). In contrast to traditional preclinical assays, genetically
engineered mouse models (GEMMs) constitute relatively novel
tools in preclinical therapeutic testing that elegantly recapitulate
the tumor microenvironment in appropriate tissue compart-
ments, thus allowing the evaluation of therapeutic efﬁcacy more
accurately (8–10). For pancreatic cancer, the LSL-KrasG12D/+;
LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mouse model was generated
with conditional mutations in both the Kras oncogene and the p53
tumor-suppressor gene analogous to the genetic mutations found
in PDA patients, and may represent a more predictive model for
preclinical evaluation compared with historical xenograft models.
KPC mice develop endogenous pancreatic adenocarcinomas with
100% penetrance and closely mimic many features of human
PDA including extensive desmoplasia, occurrence and site of
metastases, cachexia, and ascites formation (11).
We previously established a preclinical therapeutics platform
using GEMMs and demonstrated that the pronounced desmo-
plastic reaction in PDA confers an obstacle to sufﬁcient drug
delivery. The combination of Sonic Hedgehog (SHH) inhibition
by the semisynthetic cyclopamine derivative IPI-926 and gemci-
tabine resulted in stromal depletion, signiﬁcantly increased
microvessel density and patency, and improved drug delivery in
a GEMM of pancreas cancer (12). In addition, megadalton
glycosaminoglycan hyaluronan (HA) is profusely found in the
ECM of murine and human PDA and maintains a high in-
terstitial ﬂuid pressure, thus compressing blood vessels (13–15).
We and others have recently provided evidence that enzymatic
degradation of HA by PEGPH20 signiﬁcantly increased vessel
patency and perfusion without increasing the density of tumor
vessels, resulting in increased active gemcitabine levels in the
tumor (15, 16). Both the antismoothened and hyaluronidase
therapeutic approaches resulted in transient antitumor responses
and prolonged survival in the KPC mouse model. However, the
aforementioned studies could not address whether the disruption
of stromally derived factors also sensitized cancer cells to gem-
citabine. Indeed, we also recently published that γ-secretase in-
hibition synergized with gemcitabine in the same mouse PDA
model by cotargeting tumor endothelial cells and neoplastic
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cells, without increasing chemotherapy delivery (17). Therefore,
we asked whether increasing chemotherapy concentrations alone
is sufﬁcient to elicit improved response rates, or rather that ECM
modulation/degradation sensitizes tumors to the antineoplastic
properties of chemotherapy. Accordingly, we investigated the
function of connective tissue growth factor (CTGF), a protein
known to be important in stromal formation. CTGF is a pleio-
tropic and cysteine-rich matricellular protein that is abundant in
many solid malignancies including pancreas, breast, esophageal,
glioblastoma, and hepatocellular carcinoma (18–23). CTGF is
expressed in both stromal (23, 24) and neoplastic cells (25, 26) of
the pancreas, and participates in a variety of signaling pathways
that inﬂuence pancreatic stellate cell (PSC)-mediated ﬁbrogenesis
in pancreatitis and pancreatic cancer. Upon activation of proﬁ-
brogenic molecules such as TGF-β, CTGF is synthesized and
regulates integrin α5β1-dependent adhesion, migration, and col-
lagen I synthesis in PSCs (27, 28). By using an antibody directed
against CTGF, we uncouple drug delivery from stromal depletion
in KPC mice and propose that CTGF within the tumor micro-
environment mediates resistance to gemcitabine in murine PDA.
Results
Isolated Elevation of Active Gemcitabine Triphosphate Does Not
Improve Therapeutic Response in Mouse PDA. We have recently
shown that pharmacological inhibition of SHH by IPI-926 and
the enzymatic degradation of HA by PEGPH20 improved che-
motherapy delivery either through increased mean vessel density
and stromal depletion or by reexpansion and endothelial fenes-
tration formation of blood vessels, respectively (12, 16). Here we
investigated whether increased accumulation of active gemcita-
bine triphosphate (2′,2′-diﬂuorodeoxycytidine-5′-triphosphate;
dFdCTP) without additional modiﬁcations of the tumor vascu-
lature or stromal composition would be sufﬁcient to improve
therapeutic response in tumor-bearing KPC mice. Gemcitabine
is either rapidly phosphorylated inside cells to the active com-
pound dFdCTP or quickly enzymatically inactivated both inside
and outside cells from its native form (2′,2′-diﬂuorodeoxycytidine;
dFdC) to the inactivate metabolite 2′,2′-diﬂuorodeoxyuridine
(dFdU) by the enzyme cytidine deaminase (CDA), and CDA is
highly expressed in murine PDA neoplastic cells (29). First, we
established the pharmacokinetic and pharmacodynamic proﬁle
of gemcitabine metabolites in KPC mice using a highly sensitive
LC-MS/MS assay (30). Accordingly, plasma (Fig. S1A), tumor
(Fig. S1 B and C), and intestine (Fig. S1D) tissue biopsies from
KPC mice were obtained following i.p. treatment with gemcita-
bine. LC-MS/MS analysis was used to measure gemcitabine
metabolites, and the immunohistochemical detection of phos-
phohistone H3 (PH3) and cleaved caspase 3 (CC3) was used to
assess cellular proliferation and apoptosis, respectively. This
analysis revealed that the peak of apoptotic cell death coincided
with the peak of dFdCTP 2 h after gemcitabine administration
(Fig. S1 B–D), and that decreases in proliferation were nearly
complete at this time. Based upon these data, we chose to ana-
lyze all subsequent pharmacokinetic and pharmacodynamic para-
meters of gemcitabine 2 h after the last dose.
To investigate whether increasing chemotherapy concen-
trations alone is sufﬁcient to elicit improved response rates, we
used the CDA inhibitor 3,4,5,6-tetrahydrouridine (THU) (31,
32) to decrease the degradation and elimination of gemcitabine.
Gemcitabine and THU were coadministered in tumor-bearing
KPC mice, followed by the analysis of gemcitabine metabolites in
plasma and PDA tumor biopsies. Inhibition of CDA by THU
signiﬁcantly increased dFdC and decreased dFdU concentrations
in the plasma of mice (Fig. 1A). In tumor biopsies, the active,
cytotoxic metabolite dFdCTP was signiﬁcantly increased by ad-
dition of THU compared with single-agent gemcitabine (Fig.
1B). Despite 10-fold higher dFdC plasma concentrations and two
to threefold higher concentrations of intratumoral dFdCTP, the
mean content of apoptotic cells was not elevated (Fig. 1C). The
increase in dFdCTP upon THU treatment was comparable to
the results reported with PEGPH20 but cannot be directly com-
pared with the IPI-926/gemcitabine data, as a less sensitive
method of gemcitabine quantiﬁcation was used (12, 16). In addi-
tion, although prolonged treatment was precluded by increased
systemic toxicity, a randomized two-arm treatment study with
gemcitabine or gemcitabine/THU did not show signiﬁcant respon-
ses over a week as determined by tumor volume measurements
using high-resolution ultrasound (Fig. 1D). Taken together, these
results show that increasing the concentration of active gemcitabine
alone does not elicit signiﬁcant responses in murine PDA.
CTGF Is Highly Expressed in Cancer-Associated Fibroblasts and Tumor
Cells in the KPC Model. As increased accumulation of gemcitabine
alone did not yield a therapeutic beneﬁt, we reasoned that pre-
viously observed antitumor effects with SHH inhibition and HA
depletion could partly be attributed to the removal of various,
yet unidentiﬁed, survival cues within the stromal compartment of
murine pancreas tumors. Accordingly, we characterized the
Fig. 1. Pharmacological inhibition of cytidine de-
aminase with THU increases intratumoral gemcita-
bine without altering tumor growth. (A) Plasma
dFdU and dFdC concentrations in mice treated once
with gemcitabine monotherapy (n = 6) or THU/
gemcitabine combination (n = 11; *P < 0.005). (B)
Concentration of gemcitabine triphosphate (dFdCTP)
in whole-tumor samples from KPC mice treated once
with gemcitabine or THU/gemcitabine (n = 5 each
cohort; *P < 0.05). (C) Computer-based quantiﬁcation
of apoptosis (cleaved caspase 3) in individual tumors
from mice treated once with gemcitabine or THU/
gemcitabine (mean: 0.52 vs. 0.76; n = 5 each; P = 0.6).
(D) Quantiﬁcation of tumor volume growth using bi-
weekly 3D high-resolution ultrasound in mice treated
for 7 d with gemcitabine or THU/gemcitabine (mean
184.9% vs. 175.2%; n = 7 for both cohorts). All ani-
mals in A–D were killed 2 h after the last dose of
gemcitabine.
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function of CTGF in murine PDA because CTGF is expressed in
human PDA and is known to participate in a large number of
neoplastic cell–stromal interactions in cancers (23, 24). We
found CTGF to be present in KPC tumor tissue with high ex-
pression in plasma and CAFs and lower but detectable levels in
neoplastic cells (Fig. S2). Normal and metaplastic pancreata, as
well as pancreatic intraepithelial neoplasia, exhibited no or very
low CTGF content (Fig. S2A). Quantiﬁcation of CTGF in tumor
and plasma samples of KPC mice by ELISA showed a robust
increase (about 50-fold) in CTGF protein compared with normal
murine pancreas and plasma samples (Fig. S2 B and C). Western
blot analysis revealed strong CTGF protein expression in
α-smooth muscle actin (SMA)-positive and E-cadherin–negative
CAFs, whereas primary KPC tumor cells showed very low
CTGF protein (Fig. S2D). Because CTGF is overexpressed in
tumor-bearing KPC mice in a similar pattern to what has been
described in PDA patients (23, 24), this mouse model represents
a tractable experimental platform to interrogate CTGF function
in PDA.
CTGF Inhibition and Gemcitabine Reduce Tumor Burden and Induce
Apoptosis in KPC Mice. FG-3019 is a therapeutic monoclonal hu-
man antibody against CTGF that is currently under clinical in-
vestigation in pancreatic cancer patients in a phase 1/2 study
[national clinical trial (NCT)01181245]. To test the efﬁcacy of
CTGF inhibition in the KPC model, we treated mice with estab-
lished tumors of comparable size for 9 d with normal human IgG,
gemcitabine/IgG, FG-3019, or FG-3019/gemcitabine, and re-
sponse to treatment was assessed by biweekly abdominal ultra-
sound examinations (Fig. 2A and Fig. S1 E and F). Consistent
with clinical observations, gemcitabine/IgG treatment had only
marginal effects on tumor growth. Final tumor volumes in mice
treated with single-agent FG-3019 (mean: 244.7% growth, SE:
33.73) did not signiﬁcantly differ from the gemcitabine/IgG co-
hort (193.5%, SE: 16.74; P = 0.17). Treatment with FG-3019/
gemcitabine resulted in signiﬁcantly smaller tumors (117.3%, SE:
10.91) compared with gemcitabine/IgG (P < 0.02) and IgG alone
(236.7%, SE: 26.02; P < 0.002) (Fig. 2A). Tumor proliferation
was assessed, and no signiﬁcant differences were observed
among the cohorts (Fig. 2B). In contrast, levels of intratumoral
apoptosis were signiﬁcantly and substantially elevated in the
combination treatment compared with gemcitabine/IgG treat-
ment (3-fold, P < 0.005), and less substantially but still signiﬁ-
cantly increased in FG-3019–treated versus IgG-treated tumors
(1.8-fold, P < 0.02) (Fig. 2C). This increase in tumor cell apo-
ptosis is consistent with the signiﬁcantly reduced tumor burden
after 9 d of treatment in FG-3019/gemcitabine–treated mice.
Therefore, CTGF antagonism with FG-3019 and gemcitabine
treatment synergize in murine PDA.
CTGF Inhibition Targets Epithelial Tumor Cells Without Increasing
Intratumoral Gemcitabine Concentrations. As gemcitabine is known
to elicit its antitumoral effects through induction of apoptosis,
we sought to determine whether the enhanced antitumor activity
of FG-3019/gemcitabine after 9 d of treatment stemmed in part
from increased drug delivery caused by induction of apoptosis in
ﬁbroblasts and subsequent stromal collapse or stimulation of
tumor angiogenesis. Accordingly, we performed a detailed his-
tological analysis of tumors at the end point of the study (9 d) to
assess potential alterations in the cellular and acellular compo-
sition of the tumor microenvironment. Interestingly, the number
of α-SMA–positive ﬁbroblasts and the amount and composition
of collagen as determined by Picrosirius, Trichrome, and Her-
ovici staining were unchanged (Fig. S3 A–C). Furthermore, ﬁ-
bronectin and secreted protein acidic and rich in cysteine
(SPARC) were present in KPC mice (Fig. S3A) and unchanged
by FG-3019 treatment. Also, the number of CD31-positive
vessels did not signiﬁcantly differ among the treatment cohorts
(Fig. S3D). Notably, coimmunoﬂuorescence analyses revealed
that the vast majority of apoptotic cells were E-cadherin–ex-
pressing neoplastic cells rather than α-SMA–expressing stromal
cells, and these apoptotic cells were signiﬁcantly increased in
both FG-3019– and FG-3019/gemcitabine–treated mice (Fig. 2D
and Fig. S3E).
We next examined the intratumoral levels of the gemcitabine
prodrug dFdC as well as its inactivated and activated metab-
olites dFdU and dFdCTP, respectively. Interestingly, we found
that concomitant treatment with FG-3019 and gemcitabine did
not increase the levels of intratumoral gemcitabine metabolites
(Fig. S3 F–H). Therefore, we conclude that the antitumor ef-
fect observed by antagonism of secreted CTGF in combination
with gemcitabine is mediated by induction of apoptosis in
neoplastic cells without increasing gemcitabine delivery
or metabolism.
FG-3019 Decreases Expression of X-Linked Inhibitor of Apoptosis in
PDA. We investigated candidate pathways previously demon-
strated to augment pancreatic cancer cell survival, and found
that the X-linked inhibitor of apoptosis (XIAP) protein level was
markedly reduced in the lysates of FG-3019–treated KPC tumors
(Fig. 3 A and B). This effect was most pronounced in FG-3019/
gemcitabine combination-treated mice, consistent with the abil-
ity of Xiap silencing (33) or Xiap chemical inhibition (34) to
sensitize PDA cell lines to additional therapies. Xiap mRNA
levels were also signiﬁcantly reduced by FG-3019 in the presence
and absence of gemcitabine (Fig. 3C). To identify additional
genes that could plausibly participate in the sensitization to PDA
   
   
   
   
   
%
 o
f v
ol
um
e 
In
cr
ea
se
p<0.02
A B
IgG
Ge
m/
IgG
FG
-30
19
FG
-30
19
+G
em
0.0
0.5
1.0
1.5
2.0 p<0.005
p<0.03
C
IgG
IgG
/G
em
FG
30
19
FG
30
19
+G
em
%
 p
h3
 p
os
iti
ve
 c
el
ls
D
Fig. 2. FG-3019 targets CTGF to acutely decrease mouse PDA growth and
induces neoplastic cell apoptosis. (A) Quantiﬁcation of tumor volume
growth over a 9-d treatment course with biweekly 3D high-resolution ul-
trasound shows a signiﬁcant decrease in tumor burden in FG-3019/gemci-
tabine–treated mice (n = 6) compared with gemcitabine/IgG (n = 10; P =
0.01), IgG (n = 9; P < 0.002), and FG-3019 (n = 6; P < 0.003). (B) Computer-
based quantiﬁcation of proliferation (PH3) in tumors from corresponding
mice treated with IgG, gemcitabine/IgG, FG-3019, and FG-3019/gemcitabine
(n ≥ 5 per cohort; error bars represent standard deviation). (C) Computer-
based quantiﬁcation of apoptosis (cleaved caspase 3) in tumors from cor-
responding mice treated with IgG, gemcitabine/IgG, FG-3019, and FG-3019/
gemcitabine (n ≥ 6 per cohort). (D) Quantiﬁcation of E-cadherin/CC3–posi-
tive cells per high power ﬁeld (HPF) reveals a signiﬁcant increase in neo-
plastic cell apoptosis in FG-3019 (P < 0.05) and FG-3019/gemcitabine (P <
0.03) cohorts compared with gemcitabine/IgG and IgG (n ≥ 5 per cohort). All
animals were killed 2 h after the last dose of gemcitabine.
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cell death following FG-3019 treatment, we performed a whole-
genome expression analysis using bulk-tumor mRNA. Surpris-
ingly, only a small number of genes were coordinately down-
regulated more than 1.5-fold (P < 0.01) by FG-3019 and
FG-3019/gemcitabine compared with their respective control
cohorts (Fig. 3D). Importantly, our analysis conﬁrmed decreased
expression of Xiap (two separate probes), and also identiﬁed the
down-regulation of additional prosurvival transcripts such as
Birc6, Psen1, Ubqln2, and Hif1α (Fig. 3D). Therefore, the re-
duced expression of Xiap and several additional genes correlates
with FG-3019 and treatment response in murine PDA.
CTGF Inhibition in Combination with Gemcitabine Prolongs Survival
and Reduces Hemorrhagic Ascites and Liver Metastasis in KPC Mice.
To evaluate the effects of FG-3019 on intratumoral CTGF, we
analyzed tumor lysates obtained after 9 d of treatment by im-
munoblotting. Full-length CTGF (37 kDa) could be detected in
bulk-tumor lysates from treated and untreated KPC mice. Ad-
ditionally, a 15- to 20-kDa protein fragment recognized by the
CTGF antibody occurred exclusively in FG-3019– and FG-3019/
gemcitabine–treated tumors (Fig. 4A). This fragment represents
an amino-terminal cleaved CTGF fragment of uncertain func-
tion (35, 36) that is derived from the 37-kDa full-length CTGF
protein, and its presence may indicate the intratumoral binding
of CTGF by FG-3019 with exposure to extracellular proteases.
Because the prior short-term experiments with FG-3019 in-
dicated evidence of antineoplastic effects in PDA, we performed
a randomized treatment study to determine whether these
effects would translate to a survival advantage. Tumor-bearing
KPC mice were enrolled with comparable tumor volumes (Fig.
S4A), and tumor growth was monitored once per week by 3D
ultrasonography. KPC mice treated with FG-3019 alone showed
no survival beneﬁt in comparison with gemcitabine-treated
controls (11 versus 8 d). In contrast, combination treatment
with FG-3019/gemcitabine extended the median survival of
KPC mice to 29 d (Fig. 4B; P = 0.03, log-rank test). The ma-
jority of FG-3019/gemcitabine–treated KPC mice demon-
strated objective slowing of tumor growth without evidence of
obvious tumor shrinkage. In addition, FG-3019/gemcitabine
treatment resulted in a signiﬁcant decrease of hemorrhagic
ascites (4/10) compared with gemcitabine alone (13/16) at end
point (Fig. 4C; P < 0.05). Histopathological evaluation revealed
no clear differences in tumor morphology, extracellular matrix
composition, or vascular density following FG-3019/gemcita-
bine treatment. In particular, collagen I+III content as de-
termined by polarized light microscopy of Picrosirius red stains
did not show signiﬁcant differences (Fig. S4B). Interestingly,
the number and size of metastases throughout the liver were
reduced in FG-3019/gemcitabine–treated KPC mice, albeit not
in a statistically signiﬁcant manner compared with gemcitabine
monotherapy (Fig. S4C).
Discussion
As conventional and targeted treatment approaches have largely
failed to achieve substantial treatment responses in pancreatic
cancer patients, novel therapies are urgently needed in the clinic.
The notion that the pronounced desmoplastic reaction in PDA
actively contributes to the unusual refractoriness of PDA to
systemic therapies has stimulated this area of research and
revealed candidate therapeutic targets. Nonetheless, a potential
role for desmoplasia in drug resistance has been only partially
addressed, due to the multitude of signaling interactions between
tumor cells and the surrounding microenvironment (37–40).
We and others have previously shown that depletion of
abundant ECM components improves perfusion of hypovascular
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Fig. 3. FG-3019 decreases expression of XIAP in mouse PDA. (A) Western blot analysis of tumor lysates reveals decreased XIAP protein in FG-3019±gemci-
tabine cohorts following 9 d of treatment (n = 4 each). (B) Corresponding densitometry conﬁrms signiﬁcant decreases in HSP90-normalized XIAP protein
levels in FG-3019 cohorts (n = 4 each; ANOVA with Newman–Keuls posttest). (C) Xiap regulation was conﬁrmed by quantitative RT-PCR (n ≥ 5 each cohort;
ANOVA with Newman–Keuls posttest). (D) Bulk-tumor mRNA expression analysis followed by hierarchical clustering reveals 32 genes decreased (>1.5-fold, P <
0.01) by FG-3019 vs. IgG and FG-3019 + gemcitabine vs. IgG + gemcitabine for 9 d. XIAP protein levels in B correlated with mRNA expression data for cor-
responding tumors (microarrays, r > 0.57, P < 0.05).
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pancreas tumors, allowing the accumulation of higher intratumoral
drug concentrations (12, 15, 16). However, these studies could not
address whether increased drug delivery itself or the combination
of stromal modulation and chemotherapy was deterministic re-
garding the improved responses to treatment. Here we uncouple
drug delivery from stromal disruption to show that increased
intratumoral concentrations of gemcitabine are alone insufﬁcient
to overcome therapeutic resistance in murine PDA. Furthermore,
we identify CTGF as an important factor in the tumor microen-
vironment of the KPC model mediating therapeutic resistance.
Although CTGF antagonism would be hypothesized to disrupt the
ﬁbrotic architecture of PDA tumors, we instead found that FG-
3019 treatment left the stromal content grossly intact. Also, in
contrast to previous xenograft results with FG-3019 that demon-
strated antitumor activity (41, 42), treatment with FG-3019 alone
did not result in signiﬁcant antitumoral responses in KPC mice.
Previous reports have also described CTGF as a critical mediator
of vascular remodeling by regulating pericyte function and endo-
thelial basement membrane formation during angiogenesis (43).
In the tumor microenvironment, CTGF and the CXCR2 chemo-
kine ligand axis have also been implicated as promoters of tumor
angiogenesis in a variety of PDA models (42, 44). In contrast to
the prior ﬁnding that inhibition of CXCR2 resulted in reduced
CTGF levels and regulated blood vessel density and tumor growth
in the related Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2ﬂox/ﬂoxmouse model
(44), FG-3019 had no effect on mean vessel density over the time
course of treatment in KPC mice, and suggests that the relevant
therapeutic targets here are neoplastic cell-intrinsic.
CTGF antagonism with FG-3019 required the combined
treatment with gemcitabine to promote tumor stabilization and
prolong survival, indicating that CTGF provides survival cues to
PDA cells that counteract the cytotoxic response to gemcita-
bine. Indeed, candidate-based and genome-wide approaches
implicated XIAP as one potential mediator of PDA cell survival
downstream of CTGF function. XIAP belongs to the family of
inhibitor of apoptosis proteins that can directly inhibit caspases
3, 7, and 9 (45), and the strong inverse link between chemo-
therapy responsiveness and XIAP expression in several cancers
(33, 46–48) may extend our ﬁnding of a unique CTGF–XIAP
axis in murine pancreas cancer to other tumor types. The mo-
lecular details of transcriptional and posttranscriptional Xiap
regulation by CTGF in PDA may provide additional means to
increase the antineoplastic effects of FG-3019. Furthermore,
several other prosurvival genes such as Birc6, Psen1, Ubqln2,
and Hif1α were down-regulated in response to FG-3019, and
could conceivably also play a role in chemosensitivity in PDA.
The identiﬁed mechanism of increased response following
combined treatment with FG-3019 and gemcitabine is distinct
from increased gemcitabine delivery, and may also involve other
pathways known to be regulated by CTGF including stromal cell-
secreted paracrine ligands and neoplastic–stromal interactions.
Interestingly, Straussman and colleagues recently reported that
primary human diploid ﬁbroblasts suppressed the response of PDA
cell lines to gemcitabine when cocultured in vitro, but did not
identify the pathways responsible for this ﬁnding (40). This report is
consistent with our own work, where we identify CTGF as a can-
didate that modulates PDA neoplastic cell responses to gemcita-
bine via regulation of prosurvival pathways including XIAP.
These results and our prior work (17) suggest that disrupting
the stromal barrier to increase drug delivery is not required to
increase antitumor responses in murine PDA models. Rather,
increased drug delivery may be most relevant when various
intratumoral survival cues are concomitantly disrupted. We pro-
pose here that CTGF represents one such regulator of neoplastic
survival cues during gemcitabine treatment, and our results are
particularly germane given the ongoing investigational trial with
this therapeutic combination (NCT01181245). In a wider sense,
our study adds to the growing body of evidence that tumor–
stromal interactions critically contribute to innate drug resistance
observed in pancreatic cancer and other malignancies.
Materials and Methods
Additional details are provided in SI Materials and Methods.
Western Blot Analysis.Western blots were performed as previously described
(49). Densitometry was performed by scanning ﬁlms on an ImageScanner
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Fig. 4. FG-3019 targets CTGF to prolong survival when combined with gemcitabine in the KPC mouse model. (A) Western blot analysis of whole-tumor
lysates from KPC mice treated for 9 d showing a cleaved CTGF fragment (15–20 kDa) in an FG-3019–treated specimen. (B) Survival is extended by the
combination of FG-3019/gemcitabine (median survival, gemcitabine 7.5 d vs. 29 d with FG-3019/gemcitabine, *P = 0.03; FG-3019 monotherapy, 11 d). (C)
Malignant hemorrhagic ascites was signiﬁcantly decreased at end point in KPC mice treated with the combination of FG-3019/gemcitabine (n = 10; *P < 0.04,
Fisher’s exact test) compared with gemcitabine (n = 16) and FG-3019 (n = 9).
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III (GE Healthcare). Images were processed using LabScan 6.0 and
ImageQuant TL 9.0 software (GE Healthcare) to quantify signal and nor-
malize to Hsp90.
Quantitative PCR. Quantitative real-time PCR was performed on a 7900HT
Real-Time PCR System using relative quantiﬁcation (ΔΔCt) with TaqMan
assays Mm00776505_m1 and 4352341E (Applied Biosystems).
mRNA Expression Proﬁling. Tumor mRNA proﬁling was performed using
Affymetrix mouse genome 430A 2.0 arrays (Gene Expression Omnibus accession
no. GSE46203). GeneChip Robust Multiarray Averaging (GC-RMA) processed,
median normalized data were analyzed using Agilent GeneSpring GX software.
Statistical Analysis. Statistical analysis was carried out using GraphPad Prism
version 5.01 (GraphPad Software). The log-rank test was performed on the
Kaplan–Meier survival curves, and the Mann–Whitney nonparametric U test
was used for all other analyses if not indicated otherwise. Results are presented
as mean ± standard error of mean (SEM) if not indicated otherwise. P < 0.05 was
considered to be signiﬁcant.
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